Lion Point Capital’s Mersana Therapeutics MRSN Stock Holding History

Lion Point Capital’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100	Closed	-$2.89K	–	37
2025 Q4	$2.89K	Sell	100 -25,660	-100%	-$487K	0.02%	39
2025 Q3	$200K	Hold	25,760	–	–	1.14%	25
2025 Q2	$191K	Hold	25,760	–	–	1.29%	17
2025 Q1	$222K	Buy	+25,760	New	+$397K	1.41%	19
2023 Q2	–	Sell	-16,365	Closed	-$2.39M	–	33
2023 Q1	$1.68M	Buy	+16,365	New	+$2.3M	0.69%	17

Other funds holding MRSN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Lion Point Capital's MRSN Position: Q1 2026 in Review

Lion Point Capital sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 100 shares — an estimated $2.89K sold.

Lion Point Capital first reported a position in MRSN in Q1 2023 and held it in 5 quarters. The position peaked at $1.68M in Q1 2023. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.

Lion Point Capital reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
Lion Point Capital sold 100 Mersana Therapeutics shares in Q1 2026, an estimated $2.89K.
Lion Point Capital first reported a position in Mersana Therapeutics in Q1 2023 and held it in 5 quarters.
Lion Point Capital's Mersana Therapeutics position peaked at $1.68M in Q1 2023.
1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.

Based on Lion Point Capital's 13F filing for Q1 2026, filed 15 May 2026.